Johnson & Johnson

JNJ on NYSE

Sells icotrokinra (Icotyde), an oral IL-23 receptor peptide for plaque psoriasis discovered with Protagonist.

Share price

$261

Up 37% over 12 months

What analysts expect

Buy

Buy75%

Hold25%

Sell0%

Price target for the next 12 months

$275Up 8.3% compared with the current price

Price now $254Average targetLowest $210 to highest $320

25 analysts. Source: MarketBeat, 20 Oct 2026. Targets are opinions and are often wrong.

Business

Yearly revenue: $98B
Yearly profit: $21B
Company value: $631B
Forward P/E: 23.2×As of 2026-10-21
Forward P/S: 5.9×As of 2026-10-21

Revenue and profit for the last twelve months reported.

Forward P/E compares the share price with forecast earnings per share. Forward P/S compares company value with forecast revenue. Both are dated estimates, separate from the live price. Missing or non-positive estimates are shown as unavailable.

Peptides in this book

IcotrokinraPrescription